CCM
LENZ

Coldstream Capital Management’s LENZ Therapeutics LENZ Stock Holding History

Coldstream Capital Management’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-16
Closed -$412 – 3449
2025
Q1 		$412 Buy
+16
New +$394 ﹤0.01% 3394

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $143M AUM 102.52% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Coldstream Capital Management's LENZ Position: Q2 2025 in Review

Coldstream Capital Management sold out of LENZ Therapeutics (LENZ) in Q2 2025, closing a stake of 16 shares — an estimated $412 sold.

Coldstream Capital Management first reported a position in LENZ in Q1 2025 and held it in 1 quarter. The position peaked at $412 in Q1 2025. 113 funds tracked by Wall St. Rank hold LENZ as of Q2 2025.

  • Coldstream Capital Management reported no remaining LENZ Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Coldstream Capital Management sold 16 LENZ Therapeutics shares in Q2 2025, an estimated $412.
  • Coldstream Capital Management first reported a position in LENZ Therapeutics in Q1 2025 and held it in 1 quarter.
  • Coldstream Capital Management's LENZ Therapeutics position peaked at $412 in Q1 2025.
  • 113 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2025.

Based on Coldstream Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.